INDICATION
RUKOBIA, in combination with other antiretrovirals (ARVs), is indicated to treat HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current ARV regimen due to resistance, intolerance, or safety considerations.
*Prevents HIV-1 from interacting with host immune cells by binding gp120, leaving CD4+ T-cells untouched.
ATTACHMENT INHIBITOR,
AND IT MAY GIVE PATIENTS WITH LIMITED OPTIONS THEIR NEXT OPTION
GIVE PATIENTS WITH LIMITED OPTIONS THEIR NEXT OPTION



AE=adverse event; BID=twice daily; gp120=glycoprotein 120; HIV-1=human immunodeficiency virus type 1; IRIS=immune reconstitution inflammatory syndrome; MDR=multidrug-resistant; MOA=mechanism of action.
Sign Up for our next webinar
Listen to Edge of Yesterday:
A Podcast Series by ViiV Healthcare
DISCOVER RUKOBIA
BRIGHTE CLINICAL
TRIALLearn about the efficacy and safety of RUKOBIA in BRIGHTE
DOSING AND DRUG
INTERACTIONSLearn about administering RUKOBIA
ViiV MEDICAL
INFORMATIONView our medical information library if you have a question about RUKOBIA
A DEEPER LOOK AT RUKOBIA
RISKS & SIDE EFFECTS
Get information about the possible risks and side effects, including warnings and precautions and rates of discontinuation
A NOVEL
MECHANISM
OF ACTION
Learn what makes RUKOBIA a first-in-class HIV-1 attachment inhibitor1,2
EDUCATIONAL RESOURCES
View educational library for RUKOBIA, including videos and a downloadable resource
References:
- Aberg J, Shephard B, Wang, et al. Efficacy and safety of fostemsavir plus optimized background therapy in heavily treated-experienced adults with HIV-1: Week 240 results of the Phase 3 BRIGHTE study. Poster EPB160. Poster presented at; 24th International AIDS Conference; July 29-August 2, 2022; Montreal, Canada.
- Data on file ViiV Healthcare.
- Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020;7(11):740-751.
- Gartland M, et al. J Antimicrob Chemother. 2021;76(3):648-652.
FSTWCNT230012